Background. Sleep and melatonin have been associated with healthy aging. In this study, we examine the association between melatonin levels and sleep among older men. Methods. Cross-sectional study of a community-dwelling cohort of 2,821 men aged 65 years or older recruited from six U.S. centers. First morning void urine samples were collected to measure melatonin's major urinary metabolite, 6-sulfatoxymelatonin (aMT6s). We also assessed objective and subjective sleep parameters. We used logistic regression models to calculate multivariate (MV) odds ratios (ORs), and 95% confidence intervals (CIs) adjusted for important demographic variables and comorbidities. Results. In the overall sample, the only significant finding in fully adjusted models was that aMT6s levels were inversely associated with subjectively measured daytime sleepiness (sleepiness mean score of 5.79 in the top aMT6s quartile, and 6.26 in the bottom aMT6s quartile, MV OR, 1.32; 95% CI, 0.95-1.84; p trend ≤ .02). When restricting to men without β-blocker use (a known melatonin suppressant), aMT6s levels were significantly associated with shorter sleep time, that is, less than 5 hours (MV OR, = 1.90; 95% CI, 1.21-2.99; p trend = .01), and worse sleep efficiency, that is, less than
70% (MV OR, 1.58; 95% CI, 1.28-2.65; p trend < .001). aMT6s were not associated with subjective sleep quality or respiratory disturbance in any of our analyses. Conclusion. Lower nocturnal melatonin levels were associated with worsened daytime sleepiness, sleep efficiency, and shorter sleep time in older men. The role of circadian interventions, and whether melatonin levels are a modifiable risk factor for poor sleep in older men, warrants further study. Key Words: 6-Sulfatoxymelatonin-Actigraphy-Sleepiness-Total sleep time-Sleep efficiency-Older men Sleep patterns change with age. In particular, aging has been associated with shorter sleep duration, less consolidated sleep with increased awakenings, and changes in sleep architecture including less time spent in the deeper stages of sleep (1) . Previous research has associated various indicators of poor sleep with risk of mortality (2) and cardiovascular disease (3) . Specifically, a relationship between sleep disturbances, fatigue, and health complaints has been shown in a sample of community-dwelling older adults (4) . The disruption of the sleep-wake cycle among older adults may be caused in part by an agerelated decline in melatonin secretion (5) . Melatonin is a hormone, which is produced primarily in the pineal gland, almost exclusively at night (ie, in darkness) (6) . The major urinary metabolite of melatonin, 6-sulfatoxymelatonin (aMT6s), when measured in first morning urine, has been shown to accurately reflect peak and total nocturnal plasma melatonin secretion (7) Due to the ease of collecting a single urine, assessing first morning urinary aMT6s levels to reflect overall nocturnal melatonin production is much more feasible and cost-effective in the context of large-scale observational studies or randomized trials (6) as compared with repeatedly collecting nightly plasma samples, which provide more specific information on circadian rhythm.
While melatonin levels generally seem to decrease with age (5), it has been hypothesized that low melatonin levels may accelerate the aging process, increasing risk for age-related diseases and conditions (8) . A few studies support the notion that this decline may be reflective of aging-related health problems. For example, in one study mean plasma melatonin levels were similar in a group of healthy elderly men and women compared with healthy younger men (all determined "healthy" after a full clinical evaluation) (9) . Another study reported that the circadian rhythm of melatonin secretion seemed to be preserved among centenarians (10) . Studies have also suggested that melatonin may play a protective role in the development of dementia (11) , hypertension (12) , type 2 diabetes (13) , and breast cancer (14) . Hence, both sleep and melatonin have been associated with various indicators of healthy aging. Moreover, randomized control trials confirm that administration of melatonin supplements improves sleep, compared to placebo among children and adults (15) as well as older adults (16) with sleep disorders.
We examined the association between nocturnal urinary aMT6s levels and several objective and subjective sleep parameters in a large sample of community-dwelling older men. We hypothesized that higher aMT6s levels would be associated with favorable measures of sleep including longer sleep duration, more consolidated nighttime sleep, better subjective sleep quality, and less subjective daytime sleepiness.
Methods

Participants
Between 2000 and 2002, a cohort of 5,994 community-dwelling men aged above 65 years participated in the Osteoporotic Fractures in Men (MrOS) study (17, 18 The remaining 2,859 participants did not participate in the ancillary sleep study because they did not wish to participate (n = 1,997), had died before the sleep visit (n = 344), had already terminated the study (n = 36), were not eligible (n = 150), or were not invited to participate because recruitment goals had already been met (n = 332).
Participants of the ancillary sleep study were asked to complete a self-administered questionnaire and an in-clinic examination and interview. In addition, they wore a wrist actigraph for a minimum of four consecutive 24-hour periods.
aMT6s Measurements
A first morning void urine specimen was collected during the morning after the in-home overnight polysomnography (PSG) study. Instructions and supplies needed for the urine sample were provided during the in-clinic visits. Participants were instructed to keep the specimen under refrigeration until it was retrieved by a study staff member the next morning.
All aMT6s measurements were performed in the Oregon Health and Science University (OHSU) Oregon Clinical and Translational Research Institute (OCTRI) Core Laboratory. Urinary aMT6s was assayed with the Buhlman 6-sulphatoxymelatonin ELISA (ALPOC Diagnostics, Windham, NH). Assays were performed in duplicate and averaged and were repeated if the initial concentration fell off the standard curve or the duplicates did not agree. In all, 16% of the initial urine samples were repeated.
To monitor the quality of the assay, two kit controls with known concentration and a pooled urine control were included in every assay. Based on the pooled control samples, the inter-and intraassay coefficients of variation were 12.5% and 5.0%, respectively.
To account for differences arising from variations in urine concentrations, as a final step, we standardized all aMT6s levels by creatinine. Creatinine was measured in the same urine samples used for the aMT6s assays at Portland Veterans Administration Hospital clinical laboratory using a Roche COBAS Integra 6000 automated analyzer (Roche Diagnostics Corp., Indianapolis, IN). The inter-assay coefficient of variation was 2.6% based on the pooled urine samples.
Sleep Parameters
Sleep questionnaire
All participants completed sleep questionnaires including established and validated instruments. The Pittsburgh Sleep Quality Index (PSQI) (19) , a 19-item questionnaire, was used to measure subjective sleep patterns, problems, quality, latency, efficiency and napping, behavior. The Epworth Sleepiness Scale (ESS) was included to assess subjective daytime sleepiness (20) . The ESS is an eight-item scale, which asks about the likelihood of falling asleep in specific situations. The standard cutpoint of ESS is >10 for excessive daytime sleepiness (21) . PSQI and ESS have shown good reliability and validity among older men (22) . Lastly, the 30-item long Functional Outcomes of Sleep Questionnaire was included to measure the impact of sleepiness on the ability to conduct daily activities (23) . The Functional Outcomes of Sleep Questionnaire is an established instrument measuring functional limitations associated with poor sleep (24) .
Actigraphy measures
Actigraphy assessments were performed for a minimum of five consecutive 24-hour periods (25) (mean = 5.2 days, SD = 0.9 (26)) beginning with the date the clinic visit was performed. Participants wore Sleep-watch-O (Ambulatory Monitoring, Inc., Ardsley, NY) actigraphs on their nondominant wrist, recording patterns of movement using a biomorph-ceramic cantilevered beam (sensitive to 0.003 g and above), a microprocessor, 32K RAM memory, and associated circuitry. The orientation and sensitivity of the accelerometer were optimized for highly effective sleep/wake interference from wrist activity. For this report, we used data collected in digital integration mode, as this mode has been shown to correlate most strongly with the gold standard PSG among older adults (25) .
Information concerning the purpose of the test as well as instructions on wearing the actigraphy watch and completion of the corresponding sleep diary was provided to the participants at the clinic visit. Sleep diaries included questions regarding the bedtime, wake time, nap times, and information about times when the watch was removed, and they were used to edit actigraphy data. Staff members retrieved the watch from the participants' home after use. Data from the actigraphs were downloaded by certified staff members using the Action-W software (Ambulatory Monitoring, Inc.). Scoring of the actigraphy data was performed in conjunction with the sleep diary data. Compared to PSG, actigraphy shows agreement for estimating sleep and wake periods (27) . An advantage of actigraphy measurements collected over several nights in the participants' usual sleep environment is the ability to collect more representative information on certain variables, for example total sleep time (TST), as compared to PSG.
Polysomnography
A portable unit (Safiro model, Compumedics, Inc., Charlotte, NC) was used to perform 14-channel in-home, unattended overnight PSG. It was set up by trained staff members, who placed and calibrated the sensors, checked signal quality and impedance, and repositioned sensors as needed to improve signal quality (28) . Detailed methods have been previously published (28, 29) . For the present study, the severity of sleep disordered breathing is defined according to the Respiratory Disturbance Index (RDI; number of apneas and hypopneas per hour of sleep). Apneas were identified if the amplitude of the airflow was flat or nearly flat for more than 10 seconds. Hypopneas were scored based on a "discernible" (>30%) reduction in amplitude of respiratory effort or airflow, considered according to the following hierarchy: summed inductance plethysmography channel, abdominal or thoracic inductance plethysmography, nasal pressure, or thermistor. For the current study, only respiratory events (apneas and hypopneas) associated with a 3% or greater oxygen desaturation were included.
Other measures
All participants completed questionnaires including demographic variables such as age and race (Caucasian, African American, Asian, or Hispanic/other), and established instruments measuring general health and functional status, medical conditions, and health habits. The Short Form 12-item health survey (SF-12) was used to measure general health and functional status (30) . The Physical Activity Scale for the Elderly was used to assess self-reported activity (31) . In addition, participants were asked to rate their self-perceived health (excellent/good vs fair/poor/very poor). The questionnaire also included an instrument measuring depression; The Geriatric Depression Scale (32) , as well as depression and anxiety; and the Goldberg Anxiety and Depression Scales (33) . In addition, functional status was assessed by collecting information on five instrumental activities of daily living, which included walking two to three blocks on level ground, climbing up to 10 steps, preparing meals, doing heavy housework, and shopping for groceries or clothing (34) . Three different tests of cognitive function were also administered: the Modified Mini/Mental State Examination (35) , the Trail Making Test-Part B (Trails B) (36) , and the Digital Vigilance Test (37) . These tests have been described in detail elsewhere (38) . During in-clinic examinations, we measured body mass index (kg/ m 2 ) and a physical performance tests assessing time to complete a 6-m walking test. Medical conditions were assessed by calculating the sum total of prior diagnoses of common chronic illnesses (including congestive heart failure, angina, heart attack, chronic obstructive pulmonary disease, Parkinson's disease, hypertension, diabetes, and stroke). Health habits measured were smoking and alcohol use. The use of medication was assessed by asking participants to bring all current medications to their clinic visit. All prescription medications were stored in an electronic medications inventory database. Medications were matched to their ingredients based on the Iowa Drug Information Service Drug Vocabulary (College of Pharmacy, University of Iowa, Iowa City, Iowa).
Analytical Sample
A total of 2,883 sleep participants had their spot urine assayed for melatonin, 39 of which had unusable melatonin values because they were outliers. Additionally, we excluded a total of 23 participants because they reported regular use of melatonin supplements. In all, 2,821 subjects comprised the final sample of the present study. All participants signed informed consents, and the study was approved by the institutional review board at each enrollment site.
Statistical Analysis
Participants' baseline characteristics were compared across quartiles of urinary aMT6s levels using analysis of variance for normally distributed continuous variables, Kruskal-Wallis for skewed continuous data and chi-square tests for categorical data; p for trends were calculated across quartiles of melatonin. All data are presented in means and standard deviations for continuous variables and counts and as percentages for categorical variables.
The primary analysis examined associations between aMT6s levels (in quartiles) and odds of specific actigraphy and self-report measured sleep and sleepiness disturbances as binary variables. We did not investigate melatonin as a continuous variable, because melatonin was not normally distributed among the participants. In secondary analysis, we also treated measures of sleep as continuous variables. We used logistic regression models to assess the association between aMT6s levels and the following binary sleep and sleepiness outcomes: Short sleep duration (TST < 5 hours), reduced sleep efficiency (SE < 70%), excessive daytime sleepiness (ESS score >10), poor subjective sleep quality (Pittsburg Sleep Quality Index (PSQI score >5), and prevalence of respiratory disturbance index score at 3%. Odds ratios (ORs) with 95% confidence intervals (CIs) and p values for linear trends are reported, with the highest aMT6s quartile (>14.23 ng/mg creatinine) as the reference category. For continuous sleep outcomes we used least square means to calculate adjusted means across quartiles of melatonin and linear p for trend.
All primary analyses were minimally adjusted for age, site of enrollment, and body mass index. In addition, we conducted a backwards elimination stepwise procedure using all variables that were assessed in the MrOS cohort (listed in Table 1 ), which were associated with melatonin quartiles at p < .10. Of the variables, which remained in the model at a p < .05, the following 10 variables remained also at p < .10: score on the Physical Activity Scale for the Elderly (continuously), response rate on Trails B (0-300 seconds), score on the Mini/Mental State Examination (continuously), score on the modified SF-12 physical summary scale (continuously), Notes: p value is from comparison across quartiles of melatonin levels using analysis of variance for normally distributed continuous variables, Kruskal-Wallis test for skewed continuous data and chi-square tests for categorical data. BMI = body mass index, COPD = chronic obstructive pulmonary disease, DVT = Digital Vigilance Test; GDS = geriatric depression scale; HS = high school; IADL = instrumental activities of daily living, MMSE = Mini/Mental State Examination, PASE = Physical Activity Scale for the Elderly; SF-12 = Short Form 12 item health survey.
*p ≤ .05; **p ≤ .001.
hypertension (yes/no), diabetes mellitus (yes/no), congestive heart failure (yes/no), angina, use of benzodiazepines (yes/no), and total body lean mass (kg). We included these 10 covariates in our fully adjusted multivariate models. Sleep efficiency had a skewed distribution and we, therefore, transformed and normalized this variable prior to preforming the analyses. Since urination during the night is a common occurrence in the older population, this can decrease the measured accumulated melatonin in the first morning void urine samples. We performed additional analyses controlling for how often the participants got up to use the bathroom during the night. Adjusting for this variable did not change results and we, therefore, did not retain it in our primary analyses. Additionally, we ran the Hosmer and Lemeshow Goodness-of-Fit Test and all models had a p value >.05, thus, acceptable fit. Because β-blockers have been shown to decrease melatonin secretion (39), we performed additional analyses stratified by β-blocker use. We examined significant differences between β-blockers users and non-β-blockers users on all baseline characteristics. The number of men using β-blockers across the four different melatonin quartiles was 270 (38.3%) for quartile 1, 203 (28.8%) for quartile 2, 159 (22.6%) for quartile 3, and 126 (17.9%) for quartile 4. We used logistic regression models to assess the association between aMT6s levels and the same sleep and sleepiness outcomes as the main analyses for β-blockers users (n = 758) and the whole sample excluding β-blockers users (n = 2,063). These analyses were adjusted for the same 10 covariates as our main analyses. All analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC). We analyzed sleep and sleepiness disturbances as both binary and continuous outcomes, but present results from the binary analyses only in our tables (see Table 3 ).
Results
Baseline Characteristics
Baseline characteristics of 2,821 community-dwelling older men by aMT6s quartile are presented in Table 1 . The mean age of all participants was 76 years. Higher melatonin levels were associated with younger age and lower body mass index. In addition, higher melatonin levels were related to higher scores on the Physical Activity Scale for the Elderly, faster response rate on Trails B, higher scores on the Mini/Mental State Examination, faster response rate on the digit vigilance test, better self-perceived health, higher frequency of calcium supplement use, lower prevalence of hypertension, diabetes mellitus, heart attack, angina, and congestive heart failure, lower prevalence of having fallen the last year, lower prevalence of use of β-blockers, faster walk speed, and lower total body lean mass. We also assessed differences between the β-blockers users and the participants not using β-blockers users on all baseline characteristics. The β-blockers users had significantly higher age, lower Physical Activity Scale for the Elderly scores, slower response rate on Trails B, lower score on SF-12, slower response rate on the digit vigilance test, worse self-perceived health, lower frequency of calcium supplement use, higher scores on instrumental activities of daily living, lower prevalence of walk outside home, higher prevalence of hypertension, diabetes mellitus, heart attack, angina, congestive heart failure and use of benzodiazepines, slower walk speed, higher prevalence of use of calcium channel blockers, and lower prevalence of nonsteroidal antiinflammatory drug (NSAID) use than the participants who did not use β-blockers. In Table 2 , we show baseline associations between first morning urinary aMT6s level and sleep as well as sleepiness variables. Higher melatonin levels were significantly associated with higher prevalence of 5+ hours of TST, higher sleep efficiency, lower degrees of daytime sleepiness, and lower prevalence of respiratory disturbance at 3%. Mean distribution of nocturnal melatonin (aMT6s) can be found in Figure 1 .
Objectively Measured Sleep Parameters and aMT6s Level Adjusted Analyses
In the minimally adjusted model levels of aMT6s were significantly associated with objectively measured sleep duration of less than 5 hours. Men in the lowest aMT6s quartiles were more likely to sleep less than 5 hours compared with men in the highest quartile of aMT6s (eg, top vs bottom quartile, OR, 1.62; 95% CI, 1.14-2.30; p trend = .009; Table 3 ). Also, aMT6s levels were significantly related to sleep efficiency of less than 70%. Men in the lowest aMT6s quartile were more likely to experience sleep efficiency of less than 70% than men in the highest aMT6s quartile (OR, 1.41; 95% CI, 1.07-1.88; p trend = .009). AMT6s levels were not significantly associated with respiratory disturbance measured by PSG (OR, 0.93; 95% CI, 0.74-1.17; p trend = .40).
In fully adjusted analyses, the odds for sleep duration (OR, 1.44; 95% CI, 0.99-2.08; p trend = .10) and sleep efficiency (OR, 1.32; 95% CI, 0.98-1.78; p trend = .09) were no longer significant. Also in fully adjusted analyses aMT6s levels were not significantly associated with respiratory disturbance (OR, 0.89; 95% CI, 0.70-1.13; p trend = .59). Further, we observed no significant association between melatonin levels and lower sleep duration, sleep efficiency, or respiratory disturbance if the latter variables were modeled as continuous variables (data not shown).
When stratifying by regular use of β-blockers (ie, a known melatonin suppressant), aMT6s levels were not significantly related to TST and sleep efficiency in either the minimally or fully adjusted models among men who reported regular use of β--blockers. By contrast, among men without β-blocker use, we observed a significant association between aMT6s levels and TST and sleep efficiency (TST fully adjusted model: OR, 1.90; 95% CI, 1.21-2.99; p trend = .01; sleep efficiency fully adjusted model: OR, 1.84; 95% CI, 1.28-2.65; p trend = .002; p interaction = .003). Figure 1 shows the odds of sleep efficiency <70% by melatonin quartiles stratified by β-blocker use. Results remained significant after Bonferroni correction (requiring a p < .01 for significance).
Subjectively Measured Sleep and Sleepiness Parameters and aMT6s
Among all men, first morning urinary aMT6s levels were significantly associated with sleepiness scores greater than 10 in the minimally adjusted model (OR, 1.32; 95% CI, 0.95-1.84; p trend = .02; Table 3 ). However, aMT6s levels were not significantly associated with subjective sleep quality in the minimally adjusted model (OR, 1.16; 95% CI, 0.91-1.47; p trend = .02). In the fully adjusted model, the association between aMT6s levels and sleepiness scores was no longer significant (OR, 1.32; 95% CI, 0.95-1.84; p trend = .02; Table 3 ). This was also the case for the association between aMT6s levels and subjective sleep quality in the fully adjusted model (OR, 1.06; 95% CI, 0.84-1.33; p trend = .82). AMT6s levels were associated with sleepiness as a continuous variable: in the fully adjusted analysis, the mean sleepiness score was 5.79 in the top aMT6s quartile, and 6.26 in the bottom aMT6s quartile (p trend = .03). AMT6s levels were not significantly associated with subjective sleep quality (PSQI) as a continuous variable.
When stratifying by β-blocker use, melatonin was not associated with any of the subjectively measured sleep variables among men who reported regular use of β-blockers. By contrast, among men without β-blocker use, aMT6s levels were significantly associated with daytime sleepiness (fully adjusted model: OR, 1.44; 95% CI, 0.97-2.14; p trend = .02; p interaction = .05); however, this result was only borderline significant after Bonferroni correction.
Discussion
We found nocturnal melatonin secretion to be associated with daytime sleepiness in our study of sleep and sleepiness in communitydwelling older men. In our main analyses, including all men, nocturnal melatonin secretion was inversely associated with self-reported daytime sleepiness. However, the association of high melatonin levels with sleeping more than 5 hours per night, higher sleep efficiency, improved subjective sleep quality or respiratory disorders was no longer significant after multivariable adjustment. Of note, among men without β-blocker use (a known melatonin suppressant), we observed significant associations of melatonin with most sleep outcomes, and the interaction between β-blocker use and aMT6s was significant. The cross-sectional nature of our study prohibits assumptions about the direction of causality; however, it would seem more likely that low melatonin levels precede sleepiness, rather than the other way around.
Most prior research has focused on melatonin as a sleep promoting agent, mostly examining sleep timing. Previous research has examined the sleep-wake rhythm regulating functions of melatonin, confirming that melatonin promotes sleep initiation (1). Several previous studies have associated sleep-wake problems with decreased melatonin, especially among elderly subjects. Randomized controlled trials of melatonin treatment indicate that melatonin improves various sleep parameters including subjective sleep quality and latency, and morning alertness among elderly insomnia patients (16) . In one study, older women with poor sleep were shown to have lower mean evening increase in melatonin secretion and delayed melatonin onset in the evening compared with older women who slept well (40) . Moreover, blood melatonin levels were significantly reduced, sleep efficiency lower and wake after sleep onset higher in a group of elderly compared with young subjects (41) . By contrast, one study found that older individuals with sleep maintenance problems did not have lower aMT6s levels than older individuals without any sleep problems (42) . However, even though previous research on sleep and melatonin in the elderly was hampered by small sample sizes or subjective sleep assessments, overall, it suggests that melatonin mostly affects sleep by increasing nighttime sleepiness (43) .
Our study partly supports this notion, as we too found nocturnal melatonin secretion to be associated with subjectively reported daytime sleepiness. Still, reported lower daytime sleepiness levels may not be directly due to low melatonin levels, but caused by short sleep and poor sleep efficiency. However, in the present study we could not find an association between melatonin levels and short sleep and poor sleep efficiency among all men, whereas we did observe significant associations among men without β-blocker use. There were several significant differences between the β-blocker users and the nonusers in baseline characteristics, among them measures of cardiovascular disorders and other health issues. One possible explanation could be that the sample excluding the β-blockers users represents in general healthier men than the full sample. Thus, melatonin may be more important for sleep in this healthier sample, while other health issues may be affecting the sleep more than melatonin among the β-blockers users.
Sleeping for less than 5 hours or more than 9 hours has been associated with poor health among adults over 40 years of age, and in particular with a higher risk of hypertension (44) , providing some support for melatonin's role in healthy longevity (10) . Our results suggest that low melatonin levels may contribute to short sleep duration and more fragmented sleep only among men using β-blockers; whether these men used β-blocker due to hypertension is unknown.
Lower nocturnal melatonin secretion was also associated with higher odds of poor sleep efficiency among the participants who did not use β-blockers. Sleep efficiency may be an indicator of poor sleep quality. Nonetheless, in the present study, we could not find a relation between melatonin levels and subjective sleep quality, as measured by the Pittsburg Sleep Quality Index in any of our analyses. The lack of such an association may therefore either reflect a lack of sensitivity of the PSQI in the elderly or could also be reflective of discordances commonly observed between objectively and subjectively measured outcomes. Moreover, it is conceivable that older adults habituate to frequent awakenings, and thus do not perceive impairments in sleep quality. Our finding concerning the lack of an association with subjective sleep quality is in line with previous results reported by Baskett et al. (42) demonstrating that melatonin levels did not differ in older adults who had sleep maintenance problems, as identified with the Pittsburg Sleep Quality Index, compared to normal sleepers. Baskett et al. called for more research on the role of melatonin in sleep quality in older adults. The present study addresses this call and shows that melatonin does not appear to be associated with subjective sleep quality in this large group of community-dwelling older men. However, actigraphy provides evidence for poor sleep quality among the older adults with low melatonin levels in our study, and more studies are needed to confirm our findings regarding the association between melatonin and sleep quality and efficiency, especially in other populations such as older women and younger adults.
Strengths of our study include the investigation of a large sample of community-dwelling older men, who were not selected on basis of sleep disorders, with both objective and subjective measures. Moreover, we controlled for several important covariates, which strengthens the results of our study. Still, some limitations should also be considered when interpreting our results. Firstly, the study is cross-sectional in nature, thus we cannot conclude that melatonin levels affect sleep and sleepiness more than the other way around. Also, we only measured self-reported sleepiness, which can be affected by different forms of response bias. However, these possible errors are probably random with regard to melatonin levels and should, thus, not affect our results. Additionally, the instruments applied are established and validated in previous research, although some of the instruments are not wellvalidated in older adults. Moreover, some may argue that repeated samples of melatonin in plasma or saliva would be preferable over urinary aMT6s assessments. However, the use of a single first morning urinary aMT6s assessment to capture nocturnal melatonin secretion has previously been validated by previous research and among older individuals (7) . The present study is performed among men only, limiting the generalizability of our findings to women. However, it appears unlikely that the here underlying biology would differ much by gender. We used multiple outcomes and multiple comparisons in the analyses, increasing the possibility for chance findings. Because of the cross-sectional nature of our data, we cannot make any statements concerning causal pathways. Further, even though we had information on a large number of lifestyle characteristics (a unique strength of our cohort), uncontrolled confounding remains a potential source for bias in our results. Lastly, concerning the baseline associations between mean level of sleep and sleepiness outcome by quartile of aMT6s level, many of these were significant, but the differences were mostly small in magnitude and of uncertain clinical relevance.
In summary, lower melatonin levels were associated with more subjective sleepiness among older men and objectively measured shorter sleep duration and increased sleep fragmentation among older men who do not use β-blockers. The participants who did not use β-blockers seemed to be healthier than the participants who used β-blockers in general. Other large, longitudinal studies, including women as well, are needed to confirm our findings.
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